FIRST EXPERIMENTS IN SPACE FOR COVID-19 DRUG RESEARCH
The COVID-19 pandemic has generated new and urgent challenges in drug discovery and development. Veklury®, a remdesivir-based medicament invented by
Category: Uncategorized
New cyclodextrin with orphan drug designation: SBECD
ReVision Therapeutics, Inc., a privately-held, early stage biopharmaceutical company focused on the development and commercialization of innovative therapies for ocular
UK grants early access for Gilead’s remdesivir in Covid-19
The government of the U.K. is granting the country’s equivalent to an emergency use authorization to remdesivir, the antiviral drug
First copies of Gilead’s SBECD-enabled remdesivir to start selling in Bangladesh
According to Hindustan Times, Bangladesh’s Beximco Pharmaceuticals Ltd. has become the world’s first company to start selling the generic version
Gilead Announces Approval of Veklury® (remdesivir) in Japan for Patients With Severe COVID-19
Japan approved the Gilead Sciences antiviral drug remdesivir Thursday for treatment of severe COVID-19 patients, under an exceptional approval pathway
UC Berkeley, Excivion and CycloLab develop antiviral cyclodextrins against SARS-CoV-2
UC Berkeley, Excivion and Cyclolab announce a supplemental grant awarded to UC Berkeley by the National Institutes of Health to evaluate a wide
Gilead outlines plans to distribute COVID-19 drug worldwide
Gilead on Tuesday said it is negotiating with overseas drug manufacturers to license its SBECD-enabled coronavirus treatment remdesivir in an effort
SBECD-enabled Remdesivir Receives FDA’s Emergency Use Authorization for the Treatment of COVID-19
Gilead Sciences, Inc. yesterday announced that the U.S. Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for
Modulation of Plasma Membrane Composition and Microdomain Organization by methyl beta-CD in B16-F10 Mouse Melanoma Cells
The most interesting finding of Crui et al. in their recently published paper [1] for the readers of the Cyclodextrin
EMA’s recommendation on compassionate use of SBECD-enabled remdesivir for COVID-19 and Update from Gilead
During an extraordinary virtual meeting held on 2 April 2020, EMA’s human medicines committee (CHMP) gave recommendations on how the investigational antiviral